Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of povorcitinib in prurigo nodularis
jRCT2031240699Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of povorcitinib in prurigo nodularis (PN) (3 arms), sponsored by Incyte. Primary endpoint: Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24. Started Apr 2025; status: active, not recruiting.
02
Drugs
povorcitinib
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2031240699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240699.